FDA approves first rapid-acting insulin
According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...
MedPage Today7h
FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
Healio7h
FDA approves subcutaneous Merilog for glycemic control in diabetes
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
Sanofi gets FDA approval for NovoLog insulin biosimilar
Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...
FDA approves Sanofi biosimilar product for treatment of diabetes
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...
Healio12h
FDA approves Evrysdi tablets for spinal muscular atrophy
The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...
FDA Grants Fast-Track Designation To Cannabis Withdrawal Syndrome Drug
U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...
FiercePharma1d
Astellas' eye med Izervay lands key FDA label update, amping up market battle with Apellis rival
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...
MediWound Ltd.: MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...
MedPage Today8dOpinion
RFK Jr.: Here's a Way to Help 'Make America Healthy Again'
Garner is a behavioral intervention scientist and an assistant professor of nutritional sciences.
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
Nasdaq’s determination is based on the Company meeting all other applicable requirements for listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s ...